ArticleFrontiers in immunology2026
Aseptic meningitis and meningoencephalitis associated with pediatric histiocytic necrotizing lymphadenitis: a 26-case series.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Aseptic meningitis (AM) and meningoencephalitis (ME) is a rare and under recognized complication of histiocytic necrotizing lymphadenitis (HNL) in children, with no large-scale series reported. The present study aims to characterize the clinical features of HNL-AM/ME and improve recognition of this condition. Methods: We retrospectively analyzed the clinical data of children with HNL-AM/ME admitted from January 2018 to January 2026, summarizing their clinical manifestations, laboratory findings, brain magnetic resonance imaging (MRI) findings,and treatment protocols. Results: Among 797 children with HNL, 26 met criteria (23 AM, 3 ME), with a male-to-female ratio of 4.2:1. Median age at onset for all cases was 10.0 years (IQR, 6.8-12.0 years), but all ME cases were ≤6 years. All 26 presented with fever and lymphadenopathy, with a median fever duration of 26.5 days (IQR, 18.0-35.3 days), and only 4 (15.4%) cases defervesced before glucocorticoids, while neurological symptoms were the initial manifestation in 11 (42.3%) cases. Leukopenia was observed in 20 (76.9%) cases. Elevated serum ferritin (>500 μg/L) was found in 5 (19.2%) cases. All 26 patients had cerebrospinal fluid (CSF) pleocytosis (median 57.0/μL; range 16-529/μL). Elevated CSF pressure (220-280 mmH Conclusion: HNL-AM/ME predominantly affects school-aged boys. Typical features include recurrent fever, headache, leukopenia, CSF pleocytosis, linear sulcal FLAIR hyperintensity, LME, poor response to anti-infective therapy, and favorable response to glucocorticoids. Younger children (<6 years) with markedly elevated ferritin, and brain parenchymal involvement, may have a higher risk of severe disease. Early diagnosis and glucocorticoid therapy improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.